3-氯-N-(2-羟基苯基)丙酰胺 | 19343-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-N-(2-羟基苯基)丙酰胺
• 英文名称: 3-chloro-N-(2-hydroxyphenyl)propanamide
• 英文别名: 3-chloro-propionic acid-(2-hydroxy-anilide)；β-Chlor-propionsaeure-(2-oxy-anilid)；3-Chlor-propionsaeure-(2-hydroxy-anilid)；N-γ-Chlorpropionyl-o-aminophenol；3-Chlor-2'-hydroxypropananilid
• CAS: 19343-16-9
• 化学式: C₉H₁₀ClNO₂
• 分子量: 199.637
• InChiKey: FGYHFZULPYDCID-UHFFFAOYSA-N

物化性质

• 熔点：
  124-125 °C
• 沸点：
  394.7±27.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氯-N-(2-羟基苯基)丙酰胺 在 polyphosphoric acid 作用下， 生成 2-(2-Chlorethyl)benzoxazol
  参考文献：
  名称：

  Identification of a new selective dopamine D4 receptor ligand

  摘要：

  The dopamine D-4 receptor has been shown to play key roles in certain CNS pathologies including addiction to cigarette smoking. Thus, selective D-4 ligands may be useful in treating some of these conditions. Previous studies in our laboratory have indicated that the piperazine analog of haloperidol exhibits selective and increased affinity to the DAD(4) receptor subtype, in comparison to its piperidine analog. This led to further exploration of the piperazine moiety to identify new agents that are selective at the D-4 receptor. Compound 27 (KiD4 = 0.84 nM) was the most potent of the compounds tested. However, it only had moderate selectivity for the D-4 receptor. Compound 28 (KiD4 = 3.9 nM) while not as potent, was more discriminatory for the D-4 receptor subtype. In fact, compound 28 has little or no binding affinity to any of the other four DA receptor subtypes. In addition, of the 23 CNS receptors evaluated, only two, 5HT(1A)R and 5HT(2B)R, have binding affinity constants better than 100 nM (K-i < 100 nM). Compound 28 is a potentially useful D-4-selective ligand for probing disease treatments involving the D-4 receptor, such as assisting smoking cessation, reversing cognitive deficits in schizophrenia and treating erectile dysfunction. Thus, further optimization, functional characterization and evaluation in animal models may be warranted. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2014.04.026
• 作为产物：
  描述：

  2-氨基苯酚 、 3-氯丙酰氯 在 丙酮 、 水 作用下， 以 丙酮 、 水 为溶剂， 反应 0.5h， 以to give the subtitle compound (1.53 g, 77%)的产率得到3-氯-N-(2-羟基苯基)丙酰胺
  参考文献：
  名称：

  Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity

  摘要：

  本发明提供了一般式(I)的化合物，其中m，n，Z1，Z2，R1，R2，R3，R4和R5如规范中所定义；制备它们的方法；包含它们的制药组合物；以及它们在治疗中的应用。

  公开号：

  US07186718B2

文献信息

• Synthesis, evaluation and molecular modelling studies of some novel 3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(substitutedphenyl) propanamides as HIV-1 non-nucleoside reverse transcriptase inhibitors
  作者：S. Murugesan、Swastika Ganguly、Giovanni Maga

  DOI：10.1007/s12039-010-0018-7

  日期：2010.3

  elemental analysis and spectral data. All the compounds were evaluated for their HIV-1 RT inhibitory activity. Among the synthesized compounds, 3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-o-tolyl propanamide 3d and 3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(2,4,6-tribromophenyl)propanamide 3f were identified as significant inhibitors of HIV-1 reverse transcriptase with 56% and 43% residual RT activity respectively at

  通过使相应的3-氯-N-（芳基）丙酰胺反应合成了一系列新颖的十五种3-（3,4-二氢异喹啉-2（1H）-基）-N-（取代苯基）丙酰胺3（ao）。2（ao）与1,2,3,4-四氢异喹啉1的乙腈溶液。根据元素分析和光谱数据对化合物进行了表征。评价所有化合物的HIV-1 RT抑制活性。在合成的化合物中，3-（3,4-二氢异喹啉-2（1 H）-基）-无甲苯基丙酰胺3d和3-（3,4-二氢异喹啉-2（1 H））-基）-N-（2,4,6-三溴苯基）丙酰胺3f被确定为HIV-1逆转录酶的重要抑制剂，与40μM的最终浓度相比，其残留RT活性分别为56％和43％。标准药物依法韦仑。为了研究这些化合物的结合模式，还进行了HIV-1 RT（PDB ID 1rt2）对接研究。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2005054249A1

  公开（公告）日：2005-06-16

  The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  该发明提供了公式（I）中的化合物，其中m、R1、n、R2、q、X、Y、R3、R4、R5、R6、R7和R8如规范中定义，以及其制备方法、含有它们的药物组合物及其在治疗中的用途。
• Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
  申请人：——

  公开号：US20040204408A1

  公开（公告）日：2004-10-14

  The invention provides compounds of general formula (I), in which m, n, Z 1 , Z 2 , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; and their use in therapy. 1

  本发明提供通式（I）的化合物，其中m，n，Z1，Z2，R1，R2，R3，R4和R5如规范中所定义；制备它们的过程；含有它们的制药组合物；以及它们在治疗中的应用。
• Novel compounds
  申请人：Hossain Nafizal

  公开号：US20070123543A1

  公开（公告）日：2007-05-31

  The invention provides compounds of formula (I) wherein m, R 1 , n, R 2 , q, X, Y, R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供式（I）的化合物，其中m，R1，n，R2，q，X，Y，R3，R4，R5，R6，R7和R8如规范中所定义，其制备过程，包含它们的制药组合物以及它们在治疗中的使用。
• Mayer; van Zuetphen; Philipps, Chemische Berichte, 1927, vol. 60, p. 860
  作者：Mayer、van Zuetphen、Philipps

  DOI：——

  日期：——